NCT07003191

Metformin Hydrochloride and Empagliflozin Tablets in the Treatment of Type 2 Diabetes

Multicenter, Prospective, Observational Study of Metformin Hydrochloride and Empagliflozin Tablets (Enshuangping) in the Treatment of Type 2 Diabetes

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 2,600 (estimated)
• Sponsor: Sun Yat-sen University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main objective of this study is to evaluate the efficacy and safety of Metformin Hydrochloride and Empagliflozin Tablets in the treatment of type 2 diabetes in real-world clinical settings. A total of 2,600 type 2 diabetes patients were included in the study. The study observed the clinical glycemic control rate and adverse events over a period of at least 6 months from the prescription date to the end of continuous clinical follow-up.

Conditions

• Type 2 Diabetes

Interventions

Type	Name	Description
DRUG	Metformin Hydrochloride and Empagliflozin tables (Fixed-Dose Combination)	First-time treatment with Metformin Hydrochloride and Empagliflozin Tablets (metformin 500mg and empagliflozin 5mg per table) for at least 6 months

Timeline

• Start date: 2023-08-02
• Primary completion: 2025-12-31
• Completion: 2025-12-31
• First posted: 2025-06-04
• Last updated: 2025-06-04

Locations

1 site across 1 country: China